Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease

Truong, Daniel

doi:10.2147/cia.s3787

Cited by 57 publications

(30 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A follow-up of 30 patients showed that bilateral high frequency subthalamic stimulation improved insomnia symptoms [61]. Insomnia has been reported as a side effect of rotigotine [62], selegiline [63], tolcapone [64] and reboxetine [65]. In summary, controlled trials involving a large number of patients that evaluate nocturnal performance and daytime consequences are required to reach any conclusions.…”

Section: Sleep Disordersmentioning

confidence: 99%

Sleep-Wake Disturbances in Parkinson’s Disease: Current Evidence regarding Diagnostic and Therapeutic Decisions

Bruin

Bittencourt²,

Tufik³

2012

Eur Neurol

View full text Add to dashboard Cite

Sleep disorders have been frequently reported in patients with Parkinson’s disease (PD). However, there is insufficient evidence to guide precise recommendations on some diagnostic and treatment strategies. Here, we review clinical studies dealing with sleep abnormalities in PD and present clinical recommendations. Previous studies describing insomnia, excessive daytime sleepiness, narcolepsy-like episodes, circadian changes, sleep-disordered breathing, rapid eye movement sleep behavior disorder, vivid dreams and restless legs syndrome are evaluated. Longitudinal studies associating sleep disorders with PD onset or clinical deterioration are rare: only one longitudinal study associated daytime sleepiness with PD onset. Evidence suggests that clinical investigations must include direct questioning about depressive symptoms, nocturnal cramps, pain, nocturia and nighttime off periods. A patient interview must be conducted regarding sleep symptoms, including nightmares, abnormal behavior during sleep, snoring, restless legs syndrome and daytime sleepiness. Initial evidence indicates that light therapy improves motor function and depression. Advice on sleep hygiene, the treatment of concomitant depression and the careful use of dopaminergic drugs and hypnosedative agents should be considered. To date, very few controlled studies are available to make a recommendation for the management of sleep-wake disturbances in PD.

show abstract

Section: Sleep Disordersmentioning

confidence: 99%

Sleep-Wake Disturbances in Parkinson’s Disease: Current Evidence regarding Diagnostic and Therapeutic Decisions

Bruin

Bittencourt²,

Tufik³

2012

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…These findings furthermore provide the bases for considering therapeutic interventions of COMT including tolcapone, an inhibitor of COMT [62] .…”

Section: The Glutamate Hypothesis Of Schizophreniamentioning

confidence: 82%

Neurotransmitter visualization in schizophrenia

Brašić

2013

JBGC

View full text Add to dashboard Cite

Background: Although the history, interview, and examination of the patient provide the foundation for the diagnosis of schizophrenia, nuclear neuroimaging investigations constitute promising tools to elucidate the pathophysiology of schizophrenia and other neuropsychiatric disorders. Imaging studies of neuroreceptors constitute research tools to investigate the role of dysfunction of the acetylcholinergic, dopaminergic, glutamatergic, serotonergic, cannabinoid, opioid, and nicotinic systems in the pathogenesis and pathophysiology of schizophrenia and related conditions.People with the phenotype of the clinical syndrome of schizophrenia likely represent multiple distinct genotypes with poorly characterized biological traits. Thus, the population of people manifesting the clinical syndrome of schizophrenia likely contains several heterogeneous biological subgroups yet to be specified.The dopamine hypothesis of schizophrenia proposes that the positive symptoms result from an excess of intrasynaptic dopamine, an excitatory neurotransmitter, and the negative symptoms result from a deficit of intrasynaptic dopamine. Accordingly, a group of people with schizophrenia likely have reduced intrasynaptic dopamine in the tonic, resting, basal state, and increased intrasynaptic dopamine in the excited, aroused, phasic state.Additionally, the glutamate hypothesis of schizophrenia suggests that dysfunction of glutamate, another excitatory neurotransmitter, in the prefrontal region results in excessive concentrations of dopamine in the striata resulting in the positive symptoms of schizophrenia. Methodology/Principal Findings:Published research about the nuclear neuroimaging techniques to identify neurotransmitters in people with schizophrenia are reviewed.Conclusions/Significance: Future research including neuronuclear imaging and genetic evaluations is needed to characterize the biological subgroups of people with the clinical syndrome of schizophrenia. Neuronuclear imaging studies will likely refine the measurement of neurotransmitters in the presynaptic, synaptic, and postsynaptic regions in people with schizophrenia and healthy people. Imaging studies of neuroreceptors during the administration of putative therapeutic agents for schizophrenia will help determine the optimal dose. In the future the research findings summarized in this article will likely be translated into clinical practice.

show abstract

“…11 Tolcapone arrived on the market in 1997/1998 and its side effects include elevated liver transaminases and hepatotoxicity. 21 …”

Section: Tolcaponementioning

confidence: 99%

Medical therapies for motor symptoms in Parkinson’s Disease

Musey¹,

Shivkumar²

2017

MJM

View full text Add to dashboard Cite

Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease

Cited by 57 publications

References 45 publications

Sleep-Wake Disturbances in Parkinson’s Disease: Current Evidence regarding Diagnostic and Therapeutic Decisions

Sleep-Wake Disturbances in Parkinson’s Disease: Current Evidence regarding Diagnostic and Therapeutic Decisions

Neurotransmitter visualization in schizophrenia

Medical therapies for motor symptoms in Parkinson’s Disease

Contact Info

Product

Resources

About